Mycro3 is a small-molecule inhibitor of Myc-Max dimerization. The average residual tumor of Pdx1-cre/KRAS* mice after Mycro3 treatment (100mg/kg, orally, daily for 2 months) is approximately 30%.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | The proto-oncogene c-myc encodes a transcription factor c-Myc, which is of great importance in controlling cell growth and vitality[1]. The heterodimerization of c-Myc with Myc-associated factor X (MAX) plays a critical role in the proliferation, transformation, and apoptosis. Mycro3 is a small-molecule inhibitor of Myc-Max dimerization and also inhibit c-Myc/Max/DNA binding[2]. c-Myc has become an interesting and feasible target for novel therapies of a variety of human malignancies related to c-Myc, Mycro3 may be a novel and effective therapeutic agents to treat cancer. Mechanism: Mycro-3 is shown to bind one of the three discrete binding sites on the c-Myc bHLH-Zip domain[3]. |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
1.90mL 0.38mL 0.19mL |
9.49mL 1.90mL 0.95mL |
18.98mL 3.80mL 1.90mL |
CAS号 | 944547-46-0 |
分子式 | C24H17ClF2N6O4 |
分子量 | 526.879 |
别名 | |
运输 | 蓝冰 |
存储条件 |
液体 -20°C:3-6个月-80°C:12个月 粉末 Sealed in dry,Store in freezer, under -20°C |
溶解度 |
DMSO: 105 mg/mL(199.29 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO |
动物实验配方 |